• Why do omnichannel engagement models remain fragmented across marketing, sales, medical and data teams?
• How can organisations simplify overly technical omnichannel processes to make them operational for cross-functional teams and improve adoption?
• How can omnichannel processes be simplified without sacrificing the analytical depth needed to inform smarter engagement decisions?
• What data, tools and governance models best support consistent tracking of engagement models and campaigns across teams?
• How can stronger cross-functional alignment move omnichannel measurement from siloed reporting to shared, actionable insight that improves the HCP experience?  

• Where does pharma really sit today on the AI and digital maturity curve, and how does this differ across commercial, field and marketing functions? 
• Who is moving beyond GenAI into deep, operational AI, and what does day-to-day AI usage look like in practice? 
• Where is AI delivering real commercial and engagement ROI today, and what can be learned from initiatives that failed? 
• How do pharma companies implement digital solutions without risk of compliance breaches or a loss of competitive edge? 
• Why has pharma's AI and digital journey lagged behind other industries, and how can you accelerate progress despite regulatory constraints?      

Available for sponsorship - Data Analytics / Insights, CRM Platforms, Personalisation (incl AI) 

• How can organisations operationalise right message, right time, right channel using existing CRM and marketing stacks (e.g. Veeva, Salesforce) under real-world constraints?
• What is the optimal way to integrate CRM, engagement platforms and digital channels to enable coordinated, data-driven engagement?
• Which tools and analytics best support insight-sharing across functions to continuously improve customer engagement
• What are the biggest organisational, technical and regulatory obstacles to optimising channels, and how are leading companies overcoming them?
• How can orchestrated, cross-functional engagement increase trust, credibility and relevance across the HCP journey, including compliant use of social channels? 

Available for sponsorship - CRM Platforms, HCP Engagement Platforms, Marketing (overall email, app, web) 

• As HCPs and patients increasingly use LLMs to inform healthcare decisions, how can pharma future-proof its content and data strategies for an AI-mediated world?
• What practical steps can teams take today to ensure content is structured in a way that LLMs can accurately interpret and prioritise?
• What governance models are needed to ensure compliance, accuracy, and patient safety in an AI-first landscape?
• Whose responsibility is it to ensure the answers LLMs share with HCPs and patients are correct to maintain trust? 

How does it work?

Following a 25-minute panel, you will work in small groups to discuss a question posed by the speakers.

• Now that data access is no longer the primary bottleneck, how can pharma turn unstructured data into insights that directly improve HCP engagement?
• How can the AI capabilities within existing CRM platforms be used to translate data into more relevant, timely and personalised customer interactions?
• How can engagement insights generated through CRM be converted into actions, content and next-best interactions that resonate with HCPs?
• What does "good" commercial data architecture look like today, and how does maturity vary across the pharma sector?
• When does it make sense for pharma organisations to build or augment their own proprietary commercial data assets?
• How should leaders decide when to build versus buy when it comes to CRM, data platforms and commercial insight capabilities? 

How does it work? Following a 20-minute fireside chat, attendees will work in small groups to discuss a challenge posed by the speakers and share approaches from their own organisations. 

• How can pharma balance the need for consistent global scientific narratives and compliance standards with local market needs, cultural differences, and HCP preferences? 
• What role do modular content, personalisation, and AI-enabled content orchestration play in adapting global assets for local relevance without increasing complexity? 
• How can global and affiliate teams work together to improve agility, reduce approval bottlenecks, and ensure content remains timely, engaging, and impactful for HCPs? 

How does it work? During this panel discussion, have your say and get involved with live audience polling using a QR code.  

• How can AI move pharma content creation beyond static assets to adaptive, insight-led formats that genuinely reflect how HCPs want to learn and engage?
• As pharma content volumes continue to rise, how can personalisation be used as a filter, not a multiplier, to reduce noise and improve HCP engagement?
• Which digital channels, formats, and orchestration tools are pharma leaders prioritising today to deliver consumer-grade personalisation while remaining compliant and credible? 

• Does Pharma execute genuine key account management, or are most models still rooted in territory-based selling and rep-centric engagement?
• What does "true" account management look like in today's pharma environment, and how does it change the quality and outcomes of HCP interactions?
• How are leading organisations prioritising accounts, stakeholders, and resources to build deeper, longer-term relationships beyond the individual prescriber?
• Which strategies, capabilities, and success measures are proving most effective in embedding genuine KAM across commercial, medical, and digital teams? 

• Examine how AI, omnichannel, CRM and customer expectations will reshape pharma engagement and what pharma needs to prioritise now to stay ahead.
• Discover which technologies will move from experimentation to business-as-usual
• Discuss what will disappear, what will scale, and what will remain stubbornly unchanged
• Where pharma leaders should invest now, and where to hold back